PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [¹⁸F]FDG PET/CT

go back to reference Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–562CrossRefPubMed Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–562CrossRefPubMed

go back to reference Ciruelos Gil EM (2014) Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 40:862–871CrossRefPubMed Ciruelos Gil EM (2014) Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 40:862–871CrossRefPubMed

go back to reference Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224CrossRefPubMedPubMedCentral Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224CrossRefPubMedPubMedCentral

go back to reference Mukohara T (2015) PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) 7:111–123 Mukohara T (2015) PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) 7:111–123

go back to reference Hopkins BD, Pauli C, Du X, et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature Hopkins BD, Pauli C, Du X, et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature

go back to reference Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129:635–643CrossRefPubMed Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129:635–643CrossRefPubMed

go back to reference Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Ando S, Fuqua SAW (2009) Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724–4732CrossRefPubMedPubMedCentral Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Ando S, Fuqua SAW (2009) Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724–4732CrossRefPubMedPubMedCentral

go back to reference Cavazzoni A, Bonelli MA, Fumarola C, la Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, Harris AL, Martin LA, Andreis D, Bottini A, Generali D, Petronini PG (2012) Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 323:77–87CrossRefPubMed Cavazzoni A, Bonelli MA, Fumarola C, la Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, Harris AL, Martin LA, Andreis D, Bottini A, Generali D, Petronini PG (2012) Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 323:77–87CrossRefPubMed

go back to reference Loi SAR, Lee C, Luen S, Savas PColleoni M (2016) Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive, HER2- breast cancer: results from the BIG 1–98 study. In San Antonio Breast Cancer Symposium. San Antonio, United States Loi SAR, Lee C, Luen S, Savas PColleoni M (2016) Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive, HER2- breast cancer: results from the BIG 1–98 study. In San Antonio Breast Cancer Symposium. San Antonio, United States

go back to reference Ortega AD, Sanchez-Arago M, Giner-Sanchez D et al (2009) Glucose avidity of carcinomas. Cancer Lett 276:125–135CrossRefPubMed Ortega AD, Sanchez-Arago M, Giner-Sanchez D et al (2009) Glucose avidity of carcinomas. Cancer Lett 276:125–135CrossRefPubMed

go back to reference Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95CrossRefPubMed Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95CrossRefPubMed

go back to reference Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899CrossRefPubMed Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899CrossRefPubMed

go back to reference Nguyen Q-D, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human Colon carcinoma cells. Trans Oncol 4:241–248CrossRef Nguyen Q-D, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human Colon carcinoma cells. Trans Oncol 4:241–248CrossRef

go back to reference Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108:4129–4134CrossRefPubMedPubMedCentral Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108:4129–4134CrossRefPubMedPubMedCentral

go back to reference Avril N, Adler LP (2007) F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin N Am 45:645–657 viCrossRefPubMed Avril N, Adler LP (2007) F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin N Am 45:645–657 viCrossRefPubMed

go back to reference Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23:1664–1673CrossRefPubMed Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23:1664–1673CrossRefPubMed

go back to reference Adli M, Kuzhan A, Alkis H, Andic F, Yilmaz M (2013) FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis. Radiology 269:850–856CrossRefPubMed Adli M, Kuzhan A, Alkis H, Andic F, Yilmaz M (2013) FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis. Radiology 269:850–856CrossRefPubMed

go back to reference Avril S, Muzic RF Jr, Plecha D et al (2016) 18F-FDG PET/CT for monitoring of treatment response in breast Cancer. J Nucl Med 57(Suppl 1):34S–39SCrossRefPubMed Avril S, Muzic RF Jr, Plecha D et al (2016) ¹⁸F-FDG PET/CT for monitoring of treatment response in breast Cancer. J Nucl Med 57(Suppl 1):34S–39SCrossRefPubMed

go back to reference Dose Schwarz J, Bader M, Jenicke L et al (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46:1144–1150PubMed Dose Schwarz J, Bader M, Jenicke L et al (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential ¹⁸F-FDG PET. J Nucl Med 46:1144–1150PubMed

go back to reference Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P (2015) Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 20:94–104CrossRefPubMedPubMedCentral Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P (2015) Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 20:94–104CrossRefPubMedPubMedCentral

go back to reference Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Depardon E, Lassere M, Tisserand S, Fumoleau P, Brunotte F, Cochet A (2016) 18F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer. J Nucl Med 57:1707–1712CrossRefPubMed Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Depardon E, Lassere M, Tisserand S, Fumoleau P, Brunotte F, Cochet A (2016) ¹⁸F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer. J Nucl Med 57:1707–1712CrossRefPubMed

go back to reference Koolen BB, Vogel WV, Vrancken et al (2012, 2012) Molecular imaging in breast Cancer: from whole-body PET/CT to dedicated breast PET. J Oncol:438647 Koolen BB, Vogel WV, Vrancken et al (2012, 2012) Molecular imaging in breast Cancer: from whole-body PET/CT to dedicated breast PET. J Oncol:438647

go back to reference Lei L, Wang X, Chen Z (2016) PET/CT imaging for monitoring recurrence and evaluating response to treatment in breast cancer. Adv Clin Exp Med 25:377–382CrossRefPubMed Lei L, Wang X, Chen Z (2016) PET/CT imaging for monitoring recurrence and evaluating response to treatment in breast cancer. Adv Clin Exp Med 25:377–382CrossRefPubMed

go back to reference Liu Q, Wang C, Li P et al (2016) The role of 18F-FDG PET/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. Biomed Res Int 2016:3746232PubMedPubMedCentral Liu Q, Wang C, Li P et al (2016) The role of ¹⁸F-FDG PET/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. Biomed Res Int 2016:3746232PubMedPubMedCentral

go back to reference Magometschnigg HF, Baltzer PA, Fueger B, Helbich TH, Karanikas G, Dubsky P, Rudas M, Weber M, Pinker K (2015) Diagnostic accuracy of 18F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. Eur J Nucl Med Mol Imaging 42:1656–1665CrossRefPubMed Magometschnigg HF, Baltzer PA, Fueger B, Helbich TH, Karanikas G, Dubsky P, Rudas M, Weber M, Pinker K (2015) Diagnostic accuracy of ¹⁸F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. Eur J Nucl Med Mol Imaging 42:1656–1665CrossRefPubMed

go back to reference Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, le Stanc E, Edeline V, Madar O, Bellet D, Pecking AP, Alberini JL (2012) Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 39:450–460CrossRefPubMed Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, le Stanc E, Edeline V, Madar O, Bellet D, Pecking AP, Alberini JL (2012) Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 39:450–460CrossRefPubMed

go back to reference Moy L, Noz ME, Maguire GQ Jr, Ponzo F, Deans AE, Murphy-Walcott AD, Kramer EL (2007) Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans. Clin Nucl Med 32:194–198CrossRefPubMed Moy L, Noz ME, Maguire GQ Jr, Ponzo F, Deans AE, Murphy-Walcott AD, Kramer EL (2007) Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans. Clin Nucl Med 32:194–198CrossRefPubMed

go back to reference Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, Gruber S, Bickel H, Dubsky P, Bago-Horvath Z, Bartsch R, Weber M, Trattnig S, Helbich TH (2014) Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res 20:3540–3549CrossRefPubMed Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, Gruber S, Bickel H, Dubsky P, Bago-Horvath Z, Bartsch R, Weber M, Trattnig S, Helbich TH (2014) Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res 20:3540–3549CrossRefPubMed

go back to reference Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, Dickler M, Gonen M, Weber WA (2016) The impact that number of analyzed metastatic breast Cancer lesions has on response assessment by 18F-FDG PET/CT using PERCIST. J Nucl Med 57:1102–1104CrossRefPubMed Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, Dickler M, Gonen M, Weber WA (2016) The impact that number of analyzed metastatic breast Cancer lesions has on response assessment by ¹⁸F-FDG PET/CT using PERCIST. J Nucl Med 57:1102–1104CrossRefPubMed

go back to reference Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50(Suppl 1):1S–10SCrossRefPubMed Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50(Suppl 1):1S–10SCrossRefPubMed

go back to reference Yutani K, Tatsumi M, Uehara T, Nishimura T (1999) Effect of patients’ being prone during FDG PET for the diagnosis of breast cancer. AJR Am J Roentgenol 173:1337–1339CrossRefPubMed Yutani K, Tatsumi M, Uehara T, Nishimura T (1999) Effect of patients’ being prone during FDG PET for the diagnosis of breast cancer. AJR Am J Roentgenol 173:1337–1339CrossRefPubMed

go back to reference Bouin AS, Wierer M (2014) Quality standards of the European Pharmacopoeia. J Ethnopharmacol 158(Pt B):454–457CrossRefPubMed Bouin AS, Wierer M (2014) Quality standards of the European Pharmacopoeia. J Ethnopharmacol 158(Pt B):454–457CrossRefPubMed

go back to reference Hamacher K, Coenen HH (2002) Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 57:853–856CrossRefPubMed Hamacher K, Coenen HH (2002) Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 57:853–856CrossRefPubMed

go back to reference Knausl B, Hirtl A, Dobrozemsky G et al (2012) PET based volume segmentation with emphasis on the iterative TrueX algorithm. Z Med Phys 22:29–39CrossRefPubMed Knausl B, Hirtl A, Dobrozemsky G et al (2012) PET based volume segmentation with emphasis on the iterative TrueX algorithm. Z Med Phys 22:29–39CrossRefPubMed

go back to reference Knausl B, Rausch IF, Bergmann H et al (2013) Influence of PET reconstruction parameters on the TrueX algorithm. A combined phantom and patient study. Nuklearmedizin 52:28–35CrossRefPubMed Knausl B, Rausch IF, Bergmann H et al (2013) Influence of PET reconstruction parameters on the TrueX algorithm. A combined phantom and patient study. Nuklearmedizin 52:28–35CrossRefPubMed

go back to reference Rapisarda E, Bettinardi V, Thielemans K, Gilardi MC (2010) Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET. Phys Med Biol 55:4131–4151CrossRefPubMed Rapisarda E, Bettinardi V, Thielemans K, Gilardi MC (2010) Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET. Phys Med Biol 55:4131–4151CrossRefPubMed

go back to reference Graham MM, Peterson LM, Hayward RM (2000) Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27:647–655CrossRefPubMed Graham MM, Peterson LM, Hayward RM (2000) Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27:647–655CrossRefPubMed

go back to reference Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10:534–541CrossRefPubMedPubMedCentral Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10:534–541CrossRefPubMedPubMedCentral

go back to reference Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–v30CrossRefPubMed Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–v30CrossRefPubMed

go back to reference Liu YR, Jiang YZ, Zuo WJ et al (2014) PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. Onco Targets Ther 7:543–552PubMedPubMedCentral Liu YR, Jiang YZ, Zuo WJ et al (2014) PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. Onco Targets Ther 7:543–552PubMedPubMedCentral

go back to reference Pang B, Cheng S, Sun SP et al (2014) Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep 4:6255CrossRefPubMedPubMedCentral Pang B, Cheng S, Sun SP et al (2014) Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep 4:6255CrossRefPubMedPubMedCentral

go back to reference Dumont AG, Dumont SN, Trent JC (2012) The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 31:327–334CrossRefPubMedPubMedCentral Dumont AG, Dumont SN, Trent JC (2012) The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 31:327–334CrossRefPubMedPubMedCentral

go back to reference Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW, Bartlett JMS (2014) Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32:2951–2958CrossRefPubMed Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW, Bartlett JMS (2014) Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32:2951–2958CrossRefPubMed

go back to reference Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMed Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMed

go back to reference De Cicco C, Gilardi L, Botteri E et al (2013) Is [18F]fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast 22:39–43CrossRefPubMed De Cicco C, Gilardi L, Botteri E et al (2013) Is [¹⁸F]fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast 22:39–43CrossRefPubMed

go back to reference Kitajima K, Yamano T, Fukushima K et al (2016) Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. Eur J Radiol 85:943–949CrossRefPubMed Kitajima K, Yamano T, Fukushima K et al (2016) Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. Eur J Radiol 85:943–949CrossRefPubMed

go back to reference Lee J, Lee EJ, Moon SH, Kim S, Hyun SH, Cho YS, Choi JY, Kim BT, Lee KH (2017) Strong association of epidermal growth factor receptor status with breast cancer FDG uptake. Eur J Nucl Med Mol Imaging 44:1438–1447CrossRefPubMed Lee J, Lee EJ, Moon SH, Kim S, Hyun SH, Cho YS, Choi JY, Kim BT, Lee KH (2017) Strong association of epidermal growth factor receptor status with breast cancer FDG uptake. Eur J Nucl Med Mol Imaging 44:1438–1447CrossRefPubMed

go back to reference Antunovic L, Gallivanone F, Sollini M et al (2017) [18F]FDG PET/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol Imaging 44:1945–1954CrossRefPubMed Antunovic L, Gallivanone F, Sollini M et al (2017) [¹⁸F]FDG PET/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol Imaging 44:1945–1954CrossRefPubMed

go back to reference Stefano A, Gallivanone F, Messa C et al (2014) Metabolic impact of partial volume correction of [18F]FDG PET-CT oncological studies on the assessment of tumor response to treatment. Q J Nucl Med Mol Imaging 58:413–423PubMed Stefano A, Gallivanone F, Messa C et al (2014) Metabolic impact of partial volume correction of [¹⁸F]FDG PET-CT oncological studies on the assessment of tumor response to treatment. Q J Nucl Med Mol Imaging 58:413–423PubMed

go back to reference Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed

go back to reference Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GMK, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM, Akbani R, Auman JT, Balasundaram M, Balu S, Barr T, Beck A, Benz C, Benz S, Berrios M, Beroukhim R, Bodenheimer T, Boice L, Bootwalla MS, Bowen J, Bowlby R, Brooks D, Cherniack AD, Chin L, Cho J, Chudamani S, Ciriello G, Davidsen T, Demchok JA, Dennison JB, Ding L, Felau I, Ferguson ML, Frazer S, Gabriel SB, Gao JJ, Gastier-Foster JM, Gatza ML, Gehlenborg N, Gerken M, Getz G, Gibson WJ, Hayes DN, Heiman DI, Hoadley KA, Holbrook A, Holt RA, Hoyle AP, Hu H, Huang M, Hutter CM, Hwang ES, Jefferys SR, Jones SJM, Ju Z, Kim J, Lai PH, Laird PW, Lawrence MS, Leraas KM, Lichtenberg TM, Lin P, Ling S, Liu J, Liu W, Lolla L, Lu Y, Ma Y, Maglinte DT, Mardis E, Marks J, Marra MA, McAllister C, McLellan M, Meng S, Meyerson M, Mills GB, Moore RA, Mose LE, Mungall AJ, Murray BA, Naresh R, Noble MS, Oesterreich S, Olopade O, Parker JS, Perou CM, Pihl T, Saksena G, Schumacher SE, Shaw KRM, Ramirez NC, Rathmell WK, Rhie SK, Roach J, Robertson AG, Saksena G, Sander C, Schein JE, Schultz N, Shen H, Sheth M, Shi Y, Shih J, Shelley CS, Shriver C, Simons JV, Sofia HJ, Soloway MG, Sougnez C, Sun C, Tarnuzzer R, Tiezzi DG, van den Berg DJ, Voet D, Wan Y, Wang Z, Weinstein JN, Weisenberger DJ, Wilkerson MD, Wilson R, Wise L, Wiznerowicz M, Wu J, Wu Y, Yang L, Yau C, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zmuda E (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519CrossRefPubMedPubMedCentral Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GMK, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM, Akbani R, Auman JT, Balasundaram M, Balu S, Barr T, Beck A, Benz C, Benz S, Berrios M, Beroukhim R, Bodenheimer T, Boice L, Bootwalla MS, Bowen J, Bowlby R, Brooks D, Cherniack AD, Chin L, Cho J, Chudamani S, Ciriello G, Davidsen T, Demchok JA, Dennison JB, Ding L, Felau I, Ferguson ML, Frazer S, Gabriel SB, Gao JJ, Gastier-Foster JM, Gatza ML, Gehlenborg N, Gerken M, Getz G, Gibson WJ, Hayes DN, Heiman DI, Hoadley KA, Holbrook A, Holt RA, Hoyle AP, Hu H, Huang M, Hutter CM, Hwang ES, Jefferys SR, Jones SJM, Ju Z, Kim J, Lai PH, Laird PW, Lawrence MS, Leraas KM, Lichtenberg TM, Lin P, Ling S, Liu J, Liu W, Lolla L, Lu Y, Ma Y, Maglinte DT, Mardis E, Marks J, Marra MA, McAllister C, McLellan M, Meng S, Meyerson M, Mills GB, Moore RA, Mose LE, Mungall AJ, Murray BA, Naresh R, Noble MS, Oesterreich S, Olopade O, Parker JS, Perou CM, Pihl T, Saksena G, Schumacher SE, Shaw KRM, Ramirez NC, Rathmell WK, Rhie SK, Roach J, Robertson AG, Saksena G, Sander C, Schein JE, Schultz N, Shen H, Sheth M, Shi Y, Shih J, Shelley CS, Shriver C, Simons JV, Sofia HJ, Soloway MG, Sougnez C, Sun C, Tarnuzzer R, Tiezzi DG, van den Berg DJ, Voet D, Wan Y, Wang Z, Weinstein JN, Weisenberger DJ, Wilkerson MD, Wilson R, Wise L, Wiznerowicz M, Wu J, Wu Y, Yang L, Yau C, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zmuda E (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519CrossRefPubMedPubMedCentral